AUSTIN, Texas, April 25, 2022 /PRNewswire/ — VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose and monitor a range of cancers and other life-altering diseases in both humans and animals, has announced the launch of its Nu.Q® Vet Cancer Test in Asia through its appointed distributor SAGE Healthcare Private Limited.

As previously announced, SAGE was appointed in December 2021 to serve as a non-exclusive licensee and distributor for Volition’s Nu.Q® Vet Cancer Test in centralized labs in Singapore. Following pre-launch preparations, SAGE hosted a launch event featuring Professor Heather Wilson-Robles, Chief Medical Officer, Volition Veterinary, and Dr. Tom Butera, Chief Executive Officer, Volition Veterinary on Friday, April 22. SAGE is now actively marketing the Test and will be processing samples and providing test results from its centralized lab with immediate effect.

Dr. Jasmine Kway, Chief Executive Officer of Singapore Volition, commented “With rapid urbanization and rising disposable income, pets have become an important part of Asian families. Over half of the Asian population have a companion animal, with almost a third of households owning a dog. We believe that the opportunity for the Nu.Q® Vet Cancer Test is huge. SAGE Healthcare is one of the strongest and most respected distributors of leading veterinary brands in Singapore and we are delighted that the launch event was so well attended, and that active sales and marketing efforts are now underway.”

“Adding the Nu.Q® Vet Cancer Test to the routine wellness check-up for older dogs and at-risk breeds could help detect cancer early, when treatment is more effective and affordable. We believe that this is a clear unmet need in the veterinary space,” commented Ms. Irene Kum, General Manager for SAGE Healthcare Private Limited. “We are excited to launch the test in Singapore and hope to develop subsequent launch plans in other Asian markets in the future.”

Volition is developing simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including cancer in both humans and animals. For more information about Volition’s Nu.Q® technology go to: www.volition.com

About Volition

Volition is a multi-national epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop simple, easy to use, cost effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. Early diagnosis and monitoring have the potential to not only prolong the life of patients but also improve their quality of life. The tests are based on the science of Nucleosomics™, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid, which can indicate that disease is present. Volition is primarily focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.

Volition’s research and development activities are centered in Belgium, with an innovation laboratory in California and additional offices in Texas, London, and Singapore, as the company focuses on bringing its diagnostic and disease monitoring products to market.

For more information about Volition, visit Volition’s website or connect with us via Twitter, LinkedIn, and Facebook.  The contents found at Volition’s website, Twitter, LinkedIn and Facebook are not incorporated by reference into this document and should not be considered part of this document.

Media Enquiries:

Louise Batchelor/Debra Daglish, Volition, mediarelations@volition.com +44 (0)7557 774620

Investor Enquiries:

Scott Powell, Volition, investorrelations@volition.com +1 (646) 650 1351

Joseph Green, Edison Advisors, jgreen@edisongroup.com +1 (646) 653 7030

Safe Harbor Statement

Statements in this press release may be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as “expects,” “anticipates,” “intends,” “plans,” “aims,” “targets,” “believes,” “seeks,” “estimates,” “optimizing,” “potential,” “goal,” “suggests,” “can,” “could,” “would,” “should,” “may,” “will” and similar expressions identify forward-looking statements. These forward-looking statements relate to Volition’s expected market opportunity for its Nu.Q® Vet Cancer Test, the effectiveness of Volition’s blood-based diagnostic, prognostic and disease monitoring tests, Volition’s ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, and the timing and execution of product launches and publications. Volition’s actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition’s failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition’s development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition’s failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition’s intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring markets and their rapid technological change; downturns in domestic and foreign economies; and other risks identified in Volition’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition’s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

Nucleosomics™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.

Cision View original content:https://www.prnewswire.com/news-releases/volition-launches-its-nuq-vet-cancer-test-in-asia-through-its-appointed-distributor-sage-healthcare-301531770.html